Skip to main content
Heidelberg Pharma AG logo

Heidelberg Pharma AG — Investor Relations & Filings

Ticker · HPHA ISIN · DE000A11QVV0 LEI · 391200E09XYBYITR1W32 F Manufacturing
Open in API
Filings indexed 806 across all filing types
Latest filing 2025-09-04 Regulatory Filings
Country DE Germany
Listing F HPHA

About Heidelberg Pharma AG

https://heidelberg-pharma.com/en/

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Recent filings

Filing Released Lang Actions
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
Regulatory Filings Classification · 100% confidence The document is a press release issued by Heidelberg Pharma AG announcing that new clinical data for their candidate HDP-101 will be presented at an upcoming medical conference. It does not constitute a formal financial report, proxy statement, or regulatory filing required by law, but rather a corporate news announcement regarding research and development progress. As it does not fit into specific categories like earnings releases or financial reports, it falls under the general regulatory/corporate news category.
2025-09-04 English
Heidelberg Pharmas Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
Regulatory Filings Classification · 100% confidence The document is an 'Ad-hoc' announcement regarding a regulatory update from a partner (Telix Pharmaceuticals) that directly impacts the company's financial outlook (delay of a $70 million payment). It is classified as a Regulatory Filing (RNS) because it is an official disclosure of inside information under Article 17 MAR, which serves as a general regulatory announcement category for corporate news that does not fit into more specific categories like earnings releases or legal proceedings.
2025-08-28 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal notification from Heidelberg Pharma AG regarding the total number of voting rights following a conditional capital increase, as required by Article 41 of the German Securities Trading Act (WpHG). This type of regulatory disclosure regarding changes in share capital and voting rights is classified as a share issue or capital change announcement.
2025-07-31 English
Datum:31.07.2025
Audit Report / Information Classification · 95% confidence The document is a formal shareholder resolution (Gesellschafterbeschluss) regarding the exemption from financial reporting, auditing, and disclosure requirements for HDP G250 AG & Co. KG under § 264 Abs. 3 HGB. It details the company's inclusion in the consolidated financial statements of its parent company, Heidelberg Pharma AG. As this is a specific regulatory filing regarding corporate governance and reporting exemptions rather than a financial report, audit, or announcement of a report, it falls under the general regulatory filings category. FY 2024
2025-07-31 German
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.12.2023 bis zum 30.11.2024
AGM Information Classification · 99% confidence The document is a formal declaration by HDP G250 AG & Co. KG regarding the exemption from preparing, auditing, and disclosing individual financial statements for the 2024 fiscal year, pursuant to § 264 Abs. 3 HGB. It includes a shareholder resolution confirming this exemption and referencing the parent company's (Heidelberg Pharma AG) consolidated financial statements. As this is a regulatory filing concerning corporate reporting obligations and governance compliance rather than a financial report itself, it falls under the general regulatory filings category.
2025-07-31 German
Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Acquisition of 90,000 shares through the exercise of 90,000 stock options under the 2011 stock option program (tranche 2; issue 2016) for employees and me
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically Prof. Dr. Andreas Pahl, who is a member of the managing body of Heidelberg Pharma AG. It details the acquisition of 90,000 shares through the exercise of stock options. This aligns perfectly with the definition of 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2025-07-24 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.